ALLO Projected Dividend Yield
Allogene Therapeutics Inc ( NASDAQ : ALLO )Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. Co. is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. 21 YEAR PERFORMANCE RESULTS |
ALLO Dividend History Detail ALLO Dividend News ALLO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |